Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Completion of Patient Enrollment of TREAKISYM® Phase II Trial

Published: Wednesday, March 06, 2013
Last Updated: Wednesday, March 06, 2013
Bookmark and Share
Completion of enrollment in frontline low-grade non-Hodgkin’s lymphoma and mantle cell lymphoma patients.

SymBio Pharmaceuticals Limited has announced the completion of patient enrollment of its Phase II clinical trial of TREAKISYM® (bendamustine hydrochloride, SyB L-0501) in frontline low-grade non-Hodgkin’s lymphoma (NHL) and mantle cell lymphoma (MCL) patients in Japan.

This randomized trial is evaluating the combination of TREAKISYM® and rituximab versus R-CHOP.

SymBio initiated this multicenter open-label Phase II trial as a line extension study for TREAKISYM® in November, 2011, in collaboration with Eisai.

Completion of patient enrollment in this trial has occurred. “Thus far the study has progressed smoothly with no serious adverse events being reported,” said Fuminori Yoshida, President and CEO of SymBio. Trial results with data analysis and evaluation will be finalized as soon as possible.

In partnership with Eisai Co., Ltd. (Eisai), SymBio received marketing approval of TREAKISYM® (SyB L-0501) in October, 2010, for the treatment of patients with relapsed/refractory low-grade NHL and MCL in Japan.

The number of low-grade non-Hodgkin’s lymphoma patients in Japan is estimated to be approximately 11,000, including 4,000 refractory/relapsed patients and 7,000 untreated patients.

Currently, R-CHOP is prescribed as a standard therapy, however, clinical trial results in the U.S. and Europe have shown superiority of the combination of rituximab and bendamustine (R-B) over R-CHOP in terms of safety and efficacy, leading to the inclusion of R-B in the National Comprehensive Cancer Network (NCCN) guidelines, which are used by US physicians in prescribing oncology drugs.

SymBio has also initiated development of TREAKISYM® in refractory/relapsed intermediate and high-grade non-Hodgkin’s lymphoma, and refractory/relapsed multiple myeloma.

The Company also continues to pursue other indications in the hematology setting in order to maximize the potential of this ‘pipeline within a molecule’ and address other unmet medical needs.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

SymBio Initiates Japanese Phase I Trial of Oral Rigosertib (SyB C-1101) in Frontline MDS
U.S. FDA has granted orphan drug designation for the use of rigosertib in MDS.
Thursday, July 25, 2013
SymBio Initiates Japanese Phase II Trial for TREAKISYM®
Company has commenced enrollment for bendamustine in CLL patients.
Friday, May 10, 2013
CTN Accepted for SymBio’s Japan Phase 1 Trial of Rigosertib (SyB L-1101)
U.S. FDA grants orphan drug designation for using rigosertib in MDS and pancreatic cancer.
Thursday, September 27, 2012
SymBio Initiates Japan Phase 2 Trial of Bendamustine HCl (SyB L-0501) in MM
Company has achieved first patient enrollment and start phase 2 clinical trial on December 26.
Tuesday, December 27, 2011
Onconova Presents Phase I Data for Oral Rigosertib at the 53rd ASH Annual Meeting
Oral rigosertib (ON 01910.Na) advancing to Phase II.
Wednesday, December 14, 2011
SymBio Completes Patient Enrollment for Mantle Cell Lymphoma in Bendamustine Phase II Clinical Study
The Company intends to collect efficacy and safety data in preparation for NDA filing.
Monday, July 07, 2008
Scientific News
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
First Made-in-Singapore Cancer Drug Enters Clinical Testing
The drug prevents cancer progression and paves the way for new advancements in cancer therapeutics.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!